Yahoo Finance Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
James Hamilton, Chief Discovery and Translational Medicine Officer at Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), sold 6,000 shares of the company on April 1, 2024, according to a recent SEC filing. The transaction was executed at an average price of $28.03 per share, resulting in a total value of $168,180.
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that develops medicines to treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. Arrowhead's pipeline includes clinical programs in a range of disease areas such as cardiovascular, renal, hepatic, and pulmonary diseases, as well as a robust preclinical pipeline in other therapeutic areas.
Over the past year, the insider has sold a total of 55,383 shares of Arrowhead Pharmaceuticals Inc and has not made any purchases of the stock. The recent sale by James Hamilton is part of a broader pattern of insider transactions at the company. In the past year, there has been a total of 1 insider buy and 24 insider sells at Arrowhead Pharmaceuticals Inc.
On the day of the sale, Arrowhead Pharmaceuticals Inc shares closed at $28.03, giving the company a market capitalization of $3.282 billion.
The stock's price-to-GF-Value ratio stands at 1.11, indicating that Arrowhead Pharmaceuticals Inc is Fairly Valued based on its GF Value. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated considering historical trading multiples, an adjustment factor based on the company's past performance, and future business projections provided by Morningstar analysts.
The insider trend image above reflects the recent insider selling activity at Arrowhead Pharmaceuticals Inc.
The GF Value image provides a visual representation of the stock's current valuation in relation to its intrinsic value, as estimated by GuruFocus.
For more detailed information on insider transactions at Arrowhead Pharmaceuticals Inc, interested individuals can refer to the SEC filing through the provided link.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
